Compound Detail
CHEMBL517427
NILVADIPINE 🧪 Phase III
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase III
Basic Information
| ChEMBL ID | CHEMBL517427 |
| Name | NILVADIPINE |
| Phase | Phase III |
| Structure Type | MOL |
| InChI Key | FAIIFDPAEUKBEP-UHFFFAOYSA-N |
4
Targets
7
Activities
2
Assay Types
9
PK Parameters
20
Publications
17
Known Names
2
Indications
1
Mechanisms
Molecular Properties
385.4
MW (Da)
2.46
ALogP
8
HBA
1
HBD
131.6
PSA (Ų)
0.46
QED
0
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Racemic |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Voltage-gated L-type calcium channel blocker | BLOCKER | Voltage-gated L-type calcium channel | ✓ | ✓ |
Indications
Alzheimer Disease Cardiovascular Diseases
ATC Classification
C08CA10
nilvadipine
Level 1: CARDIOVASCULAR SYSTEM
Level 2: CALCIUM CHANNEL BLOCKERS
Activity Summary
EC50 5 meas. best 6.05
IC50 2 meas. best 8.98
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Voltage-gated L-type calcium channel CHEMBL2095177 | IC50 | 8.98 | 8.98 | 1.0 | 1 |
| Nuclear receptor subfamily 1 group I member 2 CHEMBL3401 | EC50 | 6.05 | 5.83 | 890.0 | 4 |
| Nuclear receptor subfamily 1 group I member 2 CHEMBL2146315 | EC50 | 4.98 | 4.98 | 10500.0 | 1 |
| ATP-dependent translocase ABCB1 CHEMBL4302 | IC50 | 4.75 | 4.75 | 18000.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 94.0 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 15.3 | mL.min-1.kg-1 | Canis lupus familiaris |
| CL | 20.0 | mL.min-1.kg-1 | Homo sapiens |
| CL | 204.7 | mL.min-1.g-1 | Homo sapiens |
| F | 20.0 | % | Homo sapiens |
| T1/2 | 40.0 | hr | - |
| T1/2 | 2.0 | hr | - |
| T1/2 | 83.33 | hr | - |
| T1/2 | 0.825 | hr | - |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 15646539 | 10.1016/s0399-8320(04)95062-2 | Unchecked | 11 |
| 20966043 | 10.1124/dmd.110.035105 | Nuclear receptor subfamily 1 group I member 2 | 9 |
| 15646539 | 10.1016/s0399-8320(04)95062-2 | NON-PROTEIN TARGET | 8 |
| - | 10.6019/CHEMBL4495565 | SARS-CoV-2 | 4 |
| 37468498 | 10.1038/s41467-023-40064-9 | Nuclear receptor subfamily 1 group I member 2 | 3 |
| 34095840 | 10.1039/d0md00097c | Unchecked | 2 |
| 2552119 | 10.1021/jm00130a029 | Canis familiaris | 2 |
| - | 10.6019/CHEMBL4495564 | Replicase polyprotein 1ab | 2 |
| - | 10.6019/CHEMBL4808148 | Histone deacetylase 6 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Gamma-aminobutyric acid receptor subunit alpha-1 | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Type-1 angiotensin II receptor | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | 5-hydroxytryptamine receptor 1A | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Mu-type opioid receptor | 2 |
| 19168354 | 10.1016/j.bmcl.2008.12.105 | Unchecked | 2 |
| 10602692 | 10.1021/jm991030j | Homo sapiens | 2 |
| 10602692 | 10.1021/jm991030j | Canis familiaris | 2 |
| 10602692 | 10.1021/jm991030j | Rattus norvegicus | 2 |
| 10891117 | 10.1021/jm0000564 | ADMET | 2 |
| 10891117 | 10.1021/jm0000564 | No relevant target | 2 |
| 37468498 | 10.1038/s41467-023-40064-9 | Muscarinic acetylcholine receptor M2 | 2 |
Data from ChEMBL 36 via Core Engine